Genenta Science S.p.A.

The Company’s shareholders also approved a reverse stock split of the Company’s ordinary shares at a ratio within a range of no. 1 new ordinary share for every no. 10 to no. 20 existing ordinary shares, together with the related amendments to Article 6 of the Company’s by-laws.

The Board has been authorized to determine, in accordance with the parameters set by the Shareholders’ Meeting resolution and within 12 months from the date of the Shareholders’ Meeting, whether to effectuate the reverse split, and if so, the specific ratio within the range approved, the effective date, and implementation of the reverse stock split, including coordinating with Euronext Securities Milan S.p.A., The Bank of New York, as depositary of the Company’s American Depositary Shares, and other applicable authorities. The reverse stock split is intended to assist the Company in maintaining compliance with Nasdaq’s minimum bid price requirement.

If the Board decides to proceed with the reverse split, the Company will announce the effective date of the reverse stock split once determined by the Board.